Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Common Equity (2017 - 2025)

Historic Common Equity for Inspire Medical Systems (INSP) over the last 9 years, with Q4 2025 value amounting to $781.2 million.

  • Inspire Medical Systems' Common Equity rose 1326.17% to $781.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $781.2 million, marking a year-over-year increase of 1326.17%. This contributed to the annual value of $781.2 million for FY2025, which is 1326.17% up from last year.
  • As of Q4 2025, Inspire Medical Systems' Common Equity stood at $781.2 million, which was up 1326.17% from $666.5 million recorded in Q3 2025.
  • Inspire Medical Systems' 5-year Common Equity high stood at $781.2 million for Q4 2025, and its period low was $219.9 million during Q2 2021.
  • Moreover, its 5-year median value for Common Equity was $536.8 million (2023), whereas its average is $491.8 million.
  • Per our database at Business Quant, Inspire Medical Systems' Common Equity plummeted by 585.63% in 2021 and then soared by 13321.42% in 2023.
  • Over the past 5 years, Inspire Medical Systems' Common Equity (Quarter) stood at $229.0 million in 2021, then skyrocketed by 116.55% to $496.0 million in 2022, then rose by 15.42% to $572.5 million in 2023, then increased by 20.47% to $689.7 million in 2024, then increased by 13.26% to $781.2 million in 2025.
  • Its last three reported values are $781.2 million in Q4 2025, $666.5 million for Q3 2025, and $677.8 million during Q2 2025.